Antiphospholipid Antibodies in Critically Ill Patients With COVID ‐19

ConclusionAntiphospholipid antibodies were common in critically ill patients with COVID ‐19. Repeated testing demonstrating medium to high titers of aPLs and the number of aPL types a patient is positive for may help in identifying patients who are at risk of developing cerebral infarction. Antiphospholipid antibodies may be transient and disappear within a few weeks, but in genetica lly predisposed patients, COVID‐19 may trigger the development of an autoimmune condition similar to the antiphospholipid syndrome (APS), referred to as “COVID‐19–induced APS‐like syndrome.” Long‐term follow‐up of COVID‐19 patients who are positive for aPLs would be of great import ance in understanding the pathogenesis of this novel coronavirus.

Source: Arthritis and Rheumatology - October 7, 2020 Category: Rheumatology Authors: Meng Xiao, Yan Zhang, Shulan Zhang, Xuzhen Qin, Peng Xia, Wei Cao, Wei Jiang, Huan Chen, Xin Ding, Hua Zhao, Hongmin Zhang, Chunyao Wang, Jing Zhao, Xuefeng Sun, Ran Tian, Wei Wu, Dong Wu, Jie Ma, Yu Chen, Dong Zhang, Jing Xie, Xiaowe Tags: Brief Report Source Type: research